Sci Simple

New Science Research Articles Everyday

# Health Sciences # Cardiovascular Medicine

The Benefits of Combination-Pill Therapy for Hypertension

Combination pills improve adherence and reduce costs for hypertension treatment.

Donglan Zhang, Jun Soo Lee, Nicole L. Therrien, Lisa M. Pollack, Sandra L. Jackson, Xiaobei Dong, Anand Rajan, Kai Hong, Andrew E. Moran, Feijun Luo

― 7 min read


Combination Pills: A Combination Pills: A Solution for Hypertension cutting healthcare costs. Improving treatment adherence while
Table of Contents

Hypertension, or high blood pressure, affects about half of Americans. It isn’t just a number; it can lead to serious health issues like heart disease, strokes, and even problems with the brain and kidneys. The common threshold for high blood pressure is 130/80 mmHg, which is about as exciting as watching paint dry, but much more important.

Interestingly, some groups, particularly Non-Hispanic Black (NHB) adults, tend to have higher rates of hypertension but don't stick to their medication as well as their Non-Hispanic White (NHW) and Hispanic counterparts. It’s like having a fantastic cake in front of you, knowing you shouldn’t eat it, yet somehow finding it hard to resist.

What is Combination-Pill Therapy?

One potential solution to this issue is something called combination-pill therapy. This fancy term just means taking two or more blood pressure medications in a single pill. Imagine trying to juggle several balls at once; it’s much easier if you just have one ball to toss. This type of therapy can help people remember to take their medications, which can sometimes feel like a part-time job with all the bottles and pills.

Guidelines from health organizations suggest starting this combination treatment right away for some people. Other countries, like those in Europe and Japan, also think it’s a good idea. They see it as a way to keep things simple and help make sure people stick to their treatment.

Challenges in the U.S.

Despite the positive outlook, many folks in the U.S. still don’t use combination-pill therapy as much as they could. Why? There are a few reasons, like certain medications not being available in health care plans, insurance issues, and maybe even some hesitations from doctors about the safety or effectiveness of these drugs. It’s a bit like trying to buy the latest gadget but finding out it’s out of stock everywhere.

This is especially tough for low-income families and people from different racial and ethnic backgrounds. They might struggle more if their insurance doesn’t cover these drugs, leading to more health problems down the road.

The Study

To get to the bottom of this, researchers looked at a large group of people using their insurance claims data. They focused on Medicaid beneficiaries to find out how combination-pill therapy affected things like taking medication as prescribed, visits to doctors or Hospitals, and overall Medical Costs.

The study focused on two main questions:

  1. How does combination-pill therapy relate to sticking to medications and healthcare use over a year?
  2. Does the effectiveness of this therapy change depending on someone’s race or ethnicity?

Data Sources and Participants

The researchers used data from a long list of Medicaid beneficiaries recorded between 2016 and 2022. They gathered people who had been diagnosed with hypertension and had received prescriptions for medications during that time. They made sure the participants were between 18 and 64 years old and were on Medicaid for the entire year they were studied.

They didn’t include anyone over 65 or pregnant women because that could complicate things. You know what they say: “If you have too many ingredients, it might spoil the soup!”

The researchers wanted to compare two groups: those taking combination pills and those on multiple separate pills. They wanted to see how patients fared in terms of taking their meds and needing medical help.

Study Focus and Outcomes

The study kept track of several important factors:

  1. Were people taking their blood pressure medications regularly?
  2. How often did they end up in the Emergency Room or the hospital for hypertension or related issues?
  3. What were the medical costs for treating hypertension or cardiovascular diseases related to hypertension?

They also looked at the money spent by Medicaid and patients themselves.

Results

A total of 325,600 adults were part of the study, and 29,328 (about 9%) were taking combination pills. Those using these combo pills were younger and more likely to be female and Non-Hispanic Black.

After crunching the numbers, the researchers found that people on combination-pill therapy were more likely to stick to their medication than those on separate pills. It was like finding out that your favorite TV show is finally getting a second season after years of waiting.

The study showed that people on combination therapy had fewer visits to the emergency room and fewer hospital stays than those on multiple medications. This was especially true among Non-Hispanic Black adults, who had more significant reductions in doctor visits compared to other groups.

Money Matters

In terms of costs, those on combination pills saved money. For example, they spent about $2,862 less on hypertension-related medical costs than those on separate pills. They saved money on both emergency room visits and hospital stays.

When it came to costs, Non-Hispanic Black people on combination therapy saved even more than their white and Hispanic peers. It’s like getting a discount on your favorite items at the store; it feels great!

However, even though the combination-pill users had lower costs overall, it turned out that the benefits weren’t evenly spread out across different racial groups. Non-Hispanic Black adults showed higher savings compared to other groups, which might indicate they really needed this therapy to reduce their medical expenses.

What Does It All Mean?

This study has important implications. It raises questions about why more people aren’t using combination pill therapy when it seems beneficial. Maybe it’s time to make more options available for these meds, like offering a larger variety of combinations, since many current options might not fit everyone's needs.

Health professionals need to find a way to ensure that combination-pill therapy is accessible and appealing to all patients, regardless of their background. After all, we all want the best care, and it should be straightforward, kind of like ordering a burger without the extra toppings you don’t want.

Limitations

Of course, the study wasn't perfect. It looked at just one year of data, so the long-term effects of combination therapy remain a mystery. Plus, the researchers couldn’t capture whether patients actually took their meds, just that they filled their prescriptions. Think of it like having a pizza delivered and not knowing if anyone actually ate it.

Also, the study focused only on Medicaid, so it might not really reflect experiences of people on private insurance. The differences in policies from state to state also play a big role in healthcare access, and the study didn’t dig into that. It’s like trying to compare apples and oranges; they’re both fruit, but they’re different.

Final Thoughts

In the end, combination-pill therapy shows a lot of promise for helping people manage their blood pressure. It improves medication adherence and reduces healthcare costs. However, there’s still work to do in making these drugs available and ensuring everyone understands their benefits.

As we move forward, it’s essential to keep in mind that everyone deserves easy access to the healthcare options that best suit them. Just like everyone deserves to enjoy a good slice of cake without worrying about the calories!

So, let’s make sure that we’re all on the same page when it comes to hypertension. Whether it’s a combination pill or a new approach, it's about keeping our hearts healthy and our blood pressure in check. Life is too short to worry about numbers, but it's also too long to ignore them!

Original Source

Title: Fixed-Dose Combination Use and Drug Adherence, Healthcare Utilization, and Costs

Abstract: BACKGROUNDCombination-pill therapy using fixed-dose combination (FDC) antihypertensives has the potential to improve hypertension control and management. However, combination-pill therapy remains low. This study aims to assess 1) the association between combination-pill therapy and subsequent medication adherence, healthcare utilization, and costs and 2) the potential to mitigate racial and ethnic disparities in medication adherence, among Medicaid beneficiaries. METHODSA retrospective cohort analysis was conducted using the 2017-2021 MerativeTM MarketScan(R) Medicaid claims database. The study sample included adults aged 18-64 years with hypertension, continuously enrolled one year before and after a random index date of prescribed antihypertensives. Combination-pill therapy was compared with multi-pill therapy. The propensity-score overlap weighting method was used to balance characteristics between individuals using combination- and multi-pill therapy. Logistic models were used for medication adherence, linear models for medication possession ratios (MPRs), negative binomial models for healthcare utilization, and generalized linear models for healthcare costs. RESULTSCompared with multi-pill therapy, combination-pill therapy was associated with improved medication adherence (3.17 in MPR, 95% CI: 2.79 - 3.55), fewer hypertension-related emergency department visits (220 per 1,000 individuals, 95% CI: -235 - -204), fewer hospitalizations (153 per 1,000 individuals, 95% CI: -160 - -146), and lower medical costs ($2,862 per person, 95% CI: -$3,035 - -$2,689). However, disparities in medication adherence between non-Hispanic White and non-Hispanic Black adults existed for both FDC and multi-pill therapy. CONCLUSIONSCombination-pill therapy could improve hypertension management and save costs for the Medicaid program and beneficiaries. These findings may inform policies on FDC antihypertensive coverage and programs. Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Authors: Donglan Zhang, Jun Soo Lee, Nicole L. Therrien, Lisa M. Pollack, Sandra L. Jackson, Xiaobei Dong, Anand Rajan, Kai Hong, Andrew E. Moran, Feijun Luo

Last Update: 2024-11-29 00:00:00

Language: English

Source URL: https://www.medrxiv.org/content/10.1101/2024.11.27.24318118

Source PDF: https://www.medrxiv.org/content/10.1101/2024.11.27.24318118.full.pdf

Licence: https://creativecommons.org/licenses/by-nc/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to medrxiv for use of its open access interoperability.

Similar Articles